Ochre Bio · Nov 2025
Ochre Bio said it completed the research phase of its GSK collaboration, delivering two human-liver datasets and moving into a multi-year co-exclusive license agreement.
RNA medicines for liver diseases
Company research
Public company, workplace, funding, and market signals
Overview
Ochre Bio is a biotechnology company developing RNA medicines for chronic liver disease. Its platform combines large human liver datasets, AI/machine learning, in-house RNA chemistry, and ex-vivo perfused human-liver models to discover and validate targets and partner with pharma.
Primary product
RNA medicines and a human-liver discovery/validation platform for chronic liver disease
Founded
2019
Headquarters
Oxford, England, United Kingdom
Team size
50-60
Work style
Onsite
Industry
Biotechnology Research
Sub-industry
RNA therapeutics for chronic liver disease
Offices
Open Positions
0 jobs at Ochre Bio
No open positions
Check back later for new openings